Carregant...
Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
PURPOSE: The purpose of this study was to report on the axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for threshold retinopathy of prematurity. METHODS: The authors conducted a comparative, consecutive, original study. RESULTS: Twenty-five ey...
Guardat en:
| Publicat a: | Clin Ophthalmol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959583/ https://ncbi.nlm.nih.gov/pubmed/27499611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S110717 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|